Ingenus plant is located in Lugano and was founded in 1997. Acquired in 2004 by APP Inc., it became Abraxis BioScience Switzerland GmbH in 2008 and in 2009 was taken over by Intraco Chemicals Ltd and renamed Pharmintraco GmbH. In 2011, Euticals S.p.A. became partner of Pharmintraco with the aim of developing finished products that are originated from molecules manufactured by them. In 2014 a new shareholder, mainly interested in the plant for developing, scale-up and manufacturing products developed by himself for the US market, became the owner of the Company. In 2016 the company adopted the new name of Ingenus Pharmaceuticals.
The plant is specialized in aseptic manufacturing of high potency injectable pharmaceutical products, liquid and lyophilized in vials, using isolator technology, and, in this sector, it has a consolidated experience in a wide range of medicinal products. Ingenus owns the Authorization for manufacture, import, wholesale trade, export and trade abroad of medicinal products released by Swissmedic. Ingenus has been also accredited by FDA and the Japanese Authorities (AFM) as a foreign drugs manufacturer.
Avyxa GmbH

We're making a difference, one product at a time.
Since 2010, Ingenus has developed, manufactured and commercialized quality generic medications as cost effective solutions for patients, suppliers and stakeholders across the healthcare continuum. Ingenus has improved patient access, offset healthcare costs and maintained high quality standards that we have become known for. This is the Ingenus difference.
Activities
Main Activity
Licensing-In (Partial)
Licensing-Out (Partial)
Co-development
Drug Product CMO
Therapeutic Areas
Cancer supportive therapy
Oncology
Markets
CH
USA and Canada
Drug Stages
Registration
Market
Generic Plus (505B2) (Partial)
Generic
Drug Product Forms
Injectable
Certifications
Swissmedic
FDA
Japan MHLW